全文获取类型
收费全文 | 604篇 |
免费 | 38篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 6篇 |
妇产科学 | 4篇 |
基础医学 | 76篇 |
口腔科学 | 9篇 |
临床医学 | 46篇 |
内科学 | 202篇 |
神经病学 | 10篇 |
特种医学 | 6篇 |
外科学 | 27篇 |
综合类 | 2篇 |
预防医学 | 11篇 |
药学 | 11篇 |
肿瘤学 | 230篇 |
出版年
2020年 | 2篇 |
2019年 | 5篇 |
2018年 | 4篇 |
2017年 | 3篇 |
2016年 | 10篇 |
2015年 | 19篇 |
2014年 | 21篇 |
2013年 | 19篇 |
2012年 | 24篇 |
2011年 | 28篇 |
2010年 | 16篇 |
2009年 | 7篇 |
2008年 | 33篇 |
2007年 | 20篇 |
2006年 | 35篇 |
2005年 | 40篇 |
2004年 | 30篇 |
2003年 | 26篇 |
2002年 | 33篇 |
2001年 | 22篇 |
2000年 | 19篇 |
1999年 | 23篇 |
1998年 | 12篇 |
1997年 | 11篇 |
1996年 | 15篇 |
1995年 | 7篇 |
1994年 | 5篇 |
1993年 | 4篇 |
1992年 | 13篇 |
1991年 | 15篇 |
1990年 | 16篇 |
1989年 | 14篇 |
1988年 | 9篇 |
1987年 | 9篇 |
1986年 | 8篇 |
1985年 | 6篇 |
1984年 | 4篇 |
1983年 | 3篇 |
1982年 | 5篇 |
1981年 | 6篇 |
1980年 | 3篇 |
1979年 | 7篇 |
1978年 | 7篇 |
1977年 | 7篇 |
1976年 | 3篇 |
1973年 | 2篇 |
1972年 | 4篇 |
1970年 | 1篇 |
1969年 | 1篇 |
1968年 | 1篇 |
排序方式: 共有642条查询结果,搜索用时 656 毫秒
21.
22.
23.
Latagliata R Breccia M Fazi P Iacobelli S Martinelli G Di Raimondo F Sborgia M Fabbiano F Pirrotta MT Zaccaria A Amadori S Caramatti C Falzetti F Candoni A Mattei D Morselli M Alimena G Vignetti M Baccarani M Mandelli F 《British journal of haematology》2008,143(5):681-689
This randomized phase III clinical trial explored the efficacy of DaunoXome (DNX) versus Daunorubicin (DNR) in acute myeloid leukaemia (AML) patients aged >60 years. Three hundred and one AML patients were randomized to receive DNR (45 mg/m(2) days 1-3) or DNX (80 mg/m(2) days 1-3) plus cytarabine (AraC; 100 mg/m(2) days 1-7). Patients in complete remission (CR) received a course of the same drugs as consolidation and then were randomized for maintenance with AraC+ all trans retinoic acid or no further treatment. Among 153 patients in the DNR arm, 78 (51.0%) achieved CR, 55 (35.9%) were resistant and 20 (13.1%) died during induction. Among 148 patients in the DNX arm, 73 (49.3%) achieved CR, 47 (31.8%) were resistant and 28 (18.9%) died during induction. Univariate analysis showed no difference as to induction results. After CR, DNX showed a higher incidence of early deaths (12.5% vs. 2.6% at 6 months, P = 0.053) but a lower incidence of relapse beyond 6 months (59% vs. 78% at 24 months, P = 0.064), with a cross in overall survival (OS) and disease-free survival (DFS) curves and a later advantage for DNX arm after 12 months from diagnosis. DNX seems to improve OS and DFS in the long-term follow-up, because of a reduction in late relapses. 相似文献
24.
CD44 ligation on peripheral blood polymorphonuclear cells induces interleukin-6 production 总被引:7,自引:0,他引:7
Sconocchia G Campagnano L Adorno D Iacona A Cococcetta NY Boffo V Amadori S Casciani CU 《Blood》2001,97(11):3621-3627
25.
A Amadori R Zamarchi M L Veronese M Panozzo M R Mazza A Barelli A Borri L Chieco-Bianchi 《AIDS (London, England)》1991,5(7):821-828
Spontaneous in vitro production of HIV-1-specific antibodies, a hallmark of infected subjects, is often down-regulated by the addition of pokeweed mitogen. We observed that a decrease in such ongoing anti-HIV-1 antibody synthesis could also be induced in cultures from most patients by addition of phytohemagglutinin and Concanavalin A, but not by Epstein-Barr virus, a selective B-cell mitogen. In most cases, this down-regulatory effect of mitogens was evident within the first 24 h of culture. The observed mitogen-associated decrease in spontaneous antibody synthesis was prevented by treating peripheral blood mononuclear cells with agents inhibiting non-major histocompatibility complex-restricted cytotoxic activity or by adding third-party cells to the cultures. In most cases, the mitogen-induced effect was also counteracted by removal of T lymphocytes or CD8+ T-cell sub-population. These findings recall a similar phenomenon observed in normal subjects following intentional immunization, and indicate that mitogen-induced down-regulation of spontaneous in vitro anti-HIV-1-antibody production most probably occurs through a lectin-dependent cytotoxic effect on activated B cells. 相似文献
26.
Mediastinal large B-cell lymphoma: clinical and immunohistological findings in 18 patients treated with different third-generation regimens 总被引:2,自引:0,他引:2
B. Falini S. Venturi M. Martelli A. Santucci S. Pileri E. Pescarmona M. Giovannini P. Mazza M. F. Martelli L. Pasqualucci E. Ballatori C. Guglielmi S. Amadori S. Poggi E. Sabattini F. Gherlinzoni P. L. Zinzani C. D. Baroni F. Mandelli S. Tura 《British journal of haematology》1995,89(4):780-789
We report on the immunophenotype, clinical findings and response to aggressive chemotherapy of 18 patients with mediastinal large B-cell lymphoma (MLCL). Cases were collected from a series of 286 high-grade non-Hodgkin's lymphomas (HG-NHL) which, in the period September 1988 to August 1991, were enrolled in a prospective multicentre trial designed to compare the MACOP-B and F-MACHOP regimens. Immunostaining on frozen sections revealed a previously unrecognized phenotype, i.e. co-expression of B-cell (CD19, CD20, CD22, Ig-associated dimer) and activation-associated antigens (CD30 and CDw70) in about 60% of MLCL cases; in contrast, the activation-associated antigens CD25 and Ki-27 (unclustered) were consistently negative. This peculiar phenotype may reflect a derivation of the tumour from a subset of thymic activated B cells. Clinically, the patients (median age 31 years; F/M ratio 2.6) presented with bulky mediastinal mass (72%) associated with mediastinal syndrome in >50% cases; disease was stage IIA in most cases. All 18 patients received aggressive chemotherapy (F-MACHOP 11; MACOP-B 7). Complete response (CR) was achieved in 57.1% of cases treated with MACOP-B. In contrast, the response of the 11 MLCL treated with F-MACHOP was poor (CR 18.2%) as compared to that of the 135 HG-NHL treated with the same regimen during the trial (CR 69.6%). This difference was still statistically significant after adjusting for negative prognostic factors (mediastinal mass > 10 cm plus increased LDH) and suggests that F-MACHOP might not be the most appropriate regimen for this kind of lymphoma. 相似文献
27.
Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia 总被引:3,自引:0,他引:3
Gattei V Bulian P Del Principe MI Zucchetto A Maurillo L Buccisano F Bomben R Dal-Bo M Luciano F Rossi FM Degan M Amadori S Del Poeta G 《Blood》2008,111(2):865-873
CD49d/alpha4-integrin is variably expressed in chronic lymphocytic leukemia (CLL). We evaluated its relevance as independent prognosticator for overall survival and time to treatment (TTT) in a series of 303 (232 for TTT) CLLs, in comparison with other biologic or clinical prognosticators (CD38, ZAP-70, immunoglobulin variable heavy chain (IGHV) gene status, cytogenetic abnormalities, soluble CD23, beta2-microglobulin, Rai staging). Flow cytometric detection of CD49d was stable and reproducible, and the chosen cut-off (30% CLL cells) easily discriminated CD49dlow from CD49dhigh cases. CD49d, whose expression was strongly associated with that of CD38 (P<.001) and ZAP-70 (P<.001), or with IGHV mutations (P<.001), was independent prognosticator for overall survival along with IGHV mutational status (CD49d hazard ratio, HRCD49d=3.52, P=.02; HRIGHV=6.53, P<.001) or, if this parameter was omitted, with ZAP-70 (HRCD49d=3.72, P=.002; HRZAP-70=3.32, P=.009). CD49d was also a prognosticator for TTT (HR=1.74, P=.007) and refined the impact of all the other factors. Notably, a CD49dhigh phenotype, although not changing the outcome of good prognosis (ZAP-70low, mutated IGHV) CLL, was necessary to correctly prognosticate the shorter TTT of ZAP-70high (HR=3.12; P=.023) or unmutated IGHV (HR=2.95; P=.002) cases. These findings support the introduction of CD49d detection in routine prognostic assessment of CLL patients, and suggest both pathogenetic and therapeutic implications for CD49d expression in CLL. 相似文献
28.
29.
Expression of cellular oncogenes in primary cells from human acute leukemias. 总被引:5,自引:2,他引:5 下载免费PDF全文
30.
Frédéric Baron Fabio Efficace Laura Cannella Petra Muus Silvia Trisolini Constantijn J. M. Halkes Paola Fazi Marco Vignetti Jean-Pierre Marie Patrizia Chiusolo Walter van der Velden Edoardo La Sala Umberto Vitolo Xavier Thomas Francois Lefrère Sr. Francesco Di Raimondo Jean-Henri Bourhis Giorgina Specchia José E. Guimarães Bernardino Allione Radovan Vrhovac Felicetto Ferrara Marian Stevens-Kroef Liv Meert Theo de Witte Roelof Willemze Sergio Amadori Stefan Suciu 《American journal of hematology》2020,95(7):749-758
We provide a long-term evaluation of patients enrolled in the EORTC/GIMEMA AML-10 trial which included a total of 2157 patients, 15-60 years old, randomized to receive either daunorubicin (DNR, 50 mg/m2), mitoxantrone (MXR, 12 mg/m2), or idarubicin (IDA, 10 mg/m2) in addition to standard-dose cytarabine and etoposide for induction chemotherapy and intermediate dose cytarabine for consolidation. Younger patients who reached complete remission with complete (CR) or incomplete (CRi) recovery were then scheduled to receive an allogeneic hematopoietic stem cell transplantation (HSCT). That was if they had a HLA-identical sibling donor; in all other cases, an autologous HSCT had to be administered. At an 11-year median follow-up, the 5-year, 10-year and 15-year overall survival (OS) rates were 33.2%, 30.1% and 28.0%, respectively. No significant difference between the three randomized groups regarding OS was observed (P = .38). In young patients, 15-45 years old, no treatment difference (P = .89) regarding OS was observed, while in patients 46-60 years old, MXR and IDA groups had a trend for a longer OS as compared to the DNR group (P = .029). Among younger patients without a favorable MRC cytogenetic risk subgroup who achieved a CR/CRi after induction chemotherapy, those with a HLA-identical sibling donor had higher 10-year and 15-year OS rates than those without. In older patients who reached CR/CRi, the long-term outcomes of those with or without a donor was similar. In conclusion, long-term outcomes of the study confirmed similar OS in the three randomized groups in the whole cohort of patients. 相似文献